At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Clinical indication for contrast-enhanced CT of head or body
- ✕Age <18 years
- ✕No clinical indication for contrast-enhanced CT
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ultravist 370 Milligrams of Iodine Per Milliliter (mg I/mL): Safety and Efficacy in Computed Tomography of Head and Body
In Brief
A Phase 3 clinical trial evaluating Iopromide 370 mg I/mL and Iopromide 300 mg I/mL for Computed Tomography and Diagnostic Imaging. Completed, enrolled 435 participants across 23 sites in 4 countries.
Detailed Summary
This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
Study Details
Timeline
Interventions
Iopromide (Ultravist 370 mg I/mL) administered intravenously
Iopromide (Ultravist 300 mg I/mL) administered intravenously